UMEDICA
GenericsUMEDICA is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology.
UMEDICA's Key Drugs
UMEDICA's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
UMEDICA's Recent FDA Approvals
New NDA/BLA approvals for UMEDICA over the last two years — novel drugs only, excluding generics and label supplements.
UMEDICA's Therapeutic Areas
UMEDICA's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UMEDICA's Top Competitors
UMEDICA's closest competitors by therapeutic-area and drug-target overlap include Novo Nordisk, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UMEDICA Pipeline Snapshot
Active clinical trials for UMEDICA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2018-05-24
- Latest
- 2026-08-05
- Applications
- 17